Phathom Pharmaceuticals, Inc. (PHAT) Stock

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc. is led by CEO Steven L. Basta, employs 427 people, headquartered in US, publicly traded since 2019.

Phathom Pharmaceuticals, Inc. (PHAT) stock trades at $11.81 with a market capitalization of $941.68M. The stock is valued at a price-to-earnings (P/E) ratio of -5.40, price-to-book of -2.79, price-to-sales of 4.45. Over the past 52 weeks the stock has ranged between $8.03 and $18.31, and currently trades 35.5% below its 52-week high.

On profitability, Phathom Pharmaceuticals, Inc. generates a return on equity (ROE) of 39.24% — well above the market average, a sign of a high-quality business, return on capital employed of -53.64%, an operating margin of -91.43%, a net profit margin of -76.77%.

Official website: www.phathompharma.com